Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when JSPR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Formal Nasdaq notice of non-compliance with minimum bid price requirement triggers delisting process with 180-day cure period.
Jasper Therapeutics receives Nasdaq delisting warning for stock price below $1.00
Filed June 9, 2026 · Period ending June 3, 2026 · ~1 min read
Key Changes
-
high
Nasdaq notified Jasper on June 3, 2026 that its stock bid price has traded below the required $1.00 minimum for 30 consecutive business days, violating listing rules. The company has until November 30, 2026 to regain compliance or face potential delisting.
Item 3.01 verify on EDGAR → -
high
Management is considering remediation options including a reverse stock split if the stock price doesn't naturally recover above $1.00. A reverse split would reduce share count and boost per-share price mechanically.
Item 3.01 verify on EDGAR → -
medium
If Jasper fails to comply by November 30, it may qualify for an additional 180-day extension, but only if it meets all other Nasdaq listing standards and commits to a reverse split if necessary.
Item 3.01 verify on EDGAR → -
medium
The deficiency notice does not immediately affect trading. Both common stock (JSPR) and warrants (JSPRW) continue trading on Nasdaq Capital Market during the 180-day compliance period.
Item 3.01 verify on EDGAR →
Summary
Jasper Therapeutics disclosed it received a formal deficiency notice from Nasdaq on June 3, 2026, warning that its common stock has traded below the required $1.00 minimum bid price for 30 consecutive business days.
This violation of Nasdaq Listing Rule 5550(a)(2) gives the company until November 30, 2026—a 180-day window—to regain compliance by maintaining a bid price of at least $1.00 for ten consecutive business days. If the stock price fails to recover naturally, management indicated it may implement a reverse stock split to mechanically boost the per-share price.
For retail investors, this is a significant warning sign about the company's market valuation and investor confidence. While trading continues normally for now, a reverse split would reduce your share count proportionally (for example, a 1-for-10 split would convert 100 shares into 10 shares at 10x the price). The company may also qualify for an additional 180-day extension if it meets other listing criteria, providing up to a year total to resolve the issue. Watch for any announcements about a reverse split proposal requiring shareholder approval, and monitor whether the stock price can sustain above $1.00 on its own—a sign of improving fundamentals or investor sentiment.
Section-by-Section Diff
Event · Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 3, 2026, Jasper Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s voting common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a) (2) (“Rule 5550(a) (2)”).
Jasper received formal notice from Nasdaq that its common stock bid price has traded below $1.00 per share for 30 consecutive business days, violating continued listing requirements. The company has until November 30, 2026 (180 days) to regain compliance by maintaining a bid price of $1.00 or more for at least ten consecutive business days. Failure to comply could lead to delisting from Nasdaq.
Added in current filing · verify on EDGAR →
The Company intends to monitor the bid price of its voting common stock and consider available options if its voting common stock does not trade at a level likely to result in the Company regaining compliance with Nasdaq’s minimum bid price rule by November 30, 2026, which may include, among other options, effectuating a reverse stock split.
Management disclosed it is considering remediation options including a potential reverse stock split if the stock price does not naturally recover to $1.00 or above. A reverse stock split would reduce share count and proportionally increase per-share price, but would dilute existing shareholders' ownership percentage if accompanied by subsequent equity issuances.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify